Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Technische Universität Dresden
- Registration Number
- NCT00923234
- Locations
- 🇩🇪
Technische Universität München, Klinikum Rechts der Isar, München, Germany
🇩🇪Medizinische Klinik und Poliklinik I, Uniklinik, Dresden, Germany
🇩🇪Universitätsklinikum Düsseldorf, Klinik für Hämatologie/Onkologie/klinische Immunologie, Düsseldorf, Germany
Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
- First Posted Date
- 2009-06-18
- Last Posted Date
- 2010-09-28
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 16
- Registration Number
- NCT00923663
- Locations
- 🇦🇹
Dept of Internal Medicine, Vienna, Austria
A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 32
- Registration Number
- NCT00915408
- Locations
- 🇬🇧
King's College Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧Royal Marsden NHS Foundation Trust, London, United Kingdom
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
- Conditions
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2019-07-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 450
- Registration Number
- NCT00910910
- Locations
- 🇺🇸
Drexel University, College of Medicine, Philadelphia, Pennsylvania, United States
🇧🇪Hopital de Jolimont, Haine-Saint Paul, Belgium
🇧🇪CHU Mont -Godinne, Yvoir, Belgium
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT00910858
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD
- Conditions
- Interventions
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2015-01-15
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 163
- Registration Number
- NCT00908232
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 15
- Registration Number
- NCT00903630
- Locations
- 🇺🇸
University of Minnesota Medical Center - Fairview, Minneapolis, Minnesota, United States
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT00899431
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2018-01-19
- Target Recruit Count
- 194
- Registration Number
- NCT00891384
- Locations
- 🇩🇪
Departement of Hematology, Oncology and Clinical Immunology, Duesseldorf, Northwest, Germany
🇩🇪Clinic of Justus-Liebig-University, Medical Clinic for Hematology and Medical Oncology, Giessen, Hessen, Germany
🇩🇪St. Johannes Hospital, Medical Clinic II, Duisburg, Northwest, Germany
Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2018-06-18
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 45
- Registration Number
- NCT00890929
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.